☆ 4.7 Article

Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy

EBIOMEDICINE (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Rheumatology

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Matthias B. Moor et al.

Summary: The study investigated immune responses to SARS-CoV-2 mRNA vaccines in patients receiving CD20-targeted B-cell-depleting therapies. Results showed blunted immune responses in these patients, indicating potential challenges in vaccination strategies for this population.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Clinical Neurology

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

Amber Salter et al.

Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Allergy

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

David Hagin et al.

Summary: The study evaluated the humoral and cellular immune response to the COVID-19 vaccine in patients with IEI, finding that most patients were able to develop vaccine-specific antibody response and S-protein-specific cellular response, and no significant adverse events were reported during the vaccination process.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis et al.

Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, Research & Experimental

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

Bezawit A. Woldemeskel et al.

Summary: Recent studies have shown that T cells can cross-recognize spike proteins of SARS-CoV-2 and common cold coronaviruses. Vaccination with SARS-CoV-2 mRNA vaccines results in broad T cell responses to the virus's spike protein, including potential recognition of variant spike proteins. Additionally, post-vaccination, there is an observed increase in CD4(+) T cell responses to certain common cold coronaviruses.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Clinical Validity of Serum Antibodies to SARS-CoV-2 A Case-Control Study

Giorgio Caturegli et al.

ANNALS OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

添加到收藏夹

Article Clinical Neurology

Multiple sclerosis management during the COVID-19 pandemic

Brandon P. Moss et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

添加到收藏夹

Article Clinical Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study

Amit Bar-Or et al.

NEUROLOGY (2020)

添加到收藏夹

Review Clinical Neurology

Effects of MS disease-modifying therapies on responses to vaccinations: A review

John Robert Ciotti et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

添加到收藏夹

Letter Immunology

Recent advances in regulatory T cells induced by B cells

Chien-Hui Chien et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2018)

添加到收藏夹

Review Immunology

Immune Regulatory Function of B Cells

Claudia Mauri et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)

添加到收藏夹

Article Rheumatology

Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial

Clifton O. Bingham et al.

ARTHRITIS AND RHEUMATISM (2010)

添加到收藏夹

Review Immunology

The who, how and where of antigen presentation to B cells

Facundo D. Batista et al.

NATURE REVIEWS IMMUNOLOGY (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.